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Case Report: A 47-year-old premenopausal unmarried woman presented with irregular menstrual bleeding and uterine mass. Sonographic
examination, suggested two uterine fibroids located in the uterine fundus and cervix measuring 4  3 cm and 3  3 cm, respectively. Total
abdominal hysterectomy with bilateral salpingo-oopherectomy was performed and the histopathology report confirmed the diagnosis of uterine
adenosarcoma with ovarian sex cord like-differentiation. The patient received neither chemotherapy nor other adjuvant therapy because the
tumor had low malignant potential, and the extent of myometrial invasion was less than half of the whole myometrium. The patient had an
uneventful recovery, and no recurrence was detected for 2 years in the follow-up period.
Conclusion: Uterine adenosarcomas mostly have relatively low malignant potential. Surgery is the optimal standard treatment for patients.
Although there is not enough data in the present literature, benign epithelial differentiations, such as sex cord-like elements may reflect the
behaviour of the tumour and shows the tendency to have a benign course in most of cases.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Keywords: Adenosarcoma; Sarcoma; Sex cord-like differentiationIntroduction
Uterine adenosarcomas are an uncommon group of stromal
mullerian neoplasms characterized by admixture of benign,
however occasionally atypical glandular epithelium and low
grade sarcoma frequently of endometrial stromal type [1].
Adenosarcoma was first described by Clement and Scully in
1974. Following this, the same authors coined the term
“mullerian adenosarcoma with sex cord-like elements” (MAS-
CEs) to encompass all uterine adenosarcoma with sex cord-like* Corresponding author. Ali Gedikbasi, Atakoy 11, Kisim, Yasemin Apt
D16, 34716 Istanbul, Turkey.
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doi:10.1016/j.tjog.2011.10.022differentiation that are closer in histogenesis to ovarian sex cord
stromal tumor [2]. Sex cord differentiation has been reported to
be more common in endometrial stromal tumors [3e5],
however, rarely reported in mullerian adenosarcomas [2,6,7]
Adenosarcomas mostly have relatively low malignant poten-
tial. Recurrences, which occur in approximately 20e30% of
cases, may be associated with high grade sarcomatous over-
growth and deep myometrial invasion [1].
Because of the small number of tumors; optimal therapy, the
prognostic factors indicating recurrence or survival of the
patients are still unclear. To our knowledge, only 11 cases of
adenosarcoma of the uterine corpus and cervix with ovarian sex
cord-like differentiation are reported in English literature. We
describe a case of uterine adenosarcoma with ovarian sex cord-
like differentiation presenting as irregular menstrual bleedingcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) Benign appearing glands in the sarcomatous stroma. (B) SCEs
appear as irregular nests and trabeculae and located especially in myometrial
invasion areas (Hematoxylin and eosin staining).
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histopathologic and immunohistochemical features.
Case report
A 47-year-old unmarried woman presented with a 6-month
history of irregular heavy menstrual bleeding. Her medical
condition was unremarkable except antiepileptic drug use for
nearly 40 years. Sonographic examination suggested two
uterine fibroids located in the uterine fundus and cervixFig. 2. Sex cord and foam cell components showed immunoreactivity for CD10
structures (C).measuring 4 3 cm and 3 3 cm, respectively. Fractional
curettage was refused by the patient because of her virginity. A
subsequent total abdominal hysterectomy with bilateral
salpingo-oopherectomy (TAH with BSO) was performed.
Macroscopically, a large cervical polyp measuring 40
30 10 mm was detected, and an intramural tumor, with
irregular margins, yellow to tan in color in the cut surfaces,
roughly 40 40 mm size was observed in the uterus. The
tumor was invading the inner half of the myometrium and
partially protruding into the uterine cavity. There was no
necrosis or hemorrhagia within the tumor. Microscopic
examination revealed a biphasic tumor composed of neoplastic
glands which were lined by benign appearing endometrioid
epithelium and low grade homologous mesenchymal compo-
nent which was formed by endometrial stromal sarcoma. The
polypoid part of the tumor, which was protruding into endo-
metrial cavity, showed a leaf-like appearance at the surface
(Fig. 1A). The stromal cells were spindle-shaped and slightly
atypical, but periglandular stromal cuffing was not obvious.
The mitotic count was 1 per 10 high power field (HPF). The
sarcomatous stroma also showed a pattern reminiscent of an
ovarian sex cord stromal tumor; the tumor cells were arranged
in bundles, nests and tubules (Fig. 1B). Additionally there
were numerous scattered sertoli-like foam cells with abundant
clear to foamy cytoplasm. This pattern constituted 20% of the
tumor volume and was located mainly in the myometrial
invasion areas. The adjacent endometrium had a proliferative
pattern as well, with focal simple hyperplasia and endome-
triosis externa was noted within the ovary.
Immunostaining techniques were performed for inhibin,
calretinin, CD10, desmin, pancytokeratin (PCK) and epithelial
membrane antigen (EMA). Endometrial stromal component was
stained focally and was weak in intensity for CD10 and PCK.
Desmin was typically positive in the myometrium while EMA
and PCK stained glandular epithelium diffusely. Additionally,
the sex cord cell and foam cell components showed focal
immunoreactivity for inhibin, calretinin and CD10 (Fig. 2).
Based on the histopathological and immunohistochemical
findings, the diagnosis was uterine adenosarcoma with ovarian
sex cord-like differentiation, and the patient received neither
chemotherapy nor other adjuvant therapy because the tumor
had low malignant potential, and the extent of myometrial
invasion was less than half of the whole myometrium. The
patient had an uneventful recovery, and no recurrence was
detected for 2 years in the follow-up period.(A) and calretinin (B). Pancytokeratin was strongly positive for glandular
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Uterine adenosarcomas represent for only 8% of all uterine
sarcomas, which comprise 1e3% of all gynecological malig-
nant tumors [1,8]. They mostly originate from the endome-
trium in 87% of patients, followed by the ovary, cervix,
myometrium and pelvis. Two thirds of patients with this tumor
are postmenopausal women, but young patients are seldom
observed especially with cases of cervical adenosarcoma [8].
Adenosarcomas are composed exclusively of homologous
mesenchymal elements such as fibroblasts and smooth muscle,
but 10e15% of the tumors have heterelogous elements like
cartilage, bone and striated muscle [9]. However, unusual
stromal differentiations such as sex-cord like elements (SCEs),
identical to those seen in endometrial stromal neoplasms
(UTROSCT) may rarely be present within the malignant
stroma of adenosarcomas (MASCEs). The biologic behavior
of MASCEs is likely to be predicted by the proportion and
appearance of the stromal cell component. Therefore, the
predominant pattern of SCEs shows the tendency to have
a benign course. The sex cord-like differentiations have been
reported in one cervical and 10 endometrial adenosarcoma
cases (Table 1) [2,6,7]. Clinically, all of the reported cases
presented with abnormal uterine bleeding. In the first series of
eight cases, SCEs ranged from several microscopic foci (<5%
of the tumor) to approximately 50% of the tumors [2]. In
contrast, in another case report of two cases, uterine adeno-
sarcoma was massively overgrown by SCEs that constituted
more than 75% of the tumors [7]. In the present case SCEs
were multifocal and accounted for 20% of the tumor volume.
In view of the similarity in tumor biology, treatment options
are similar to endometrial stromal sarcoma [10], therefore
standard treatment is TAH with BSO. In addition to this
approach, the other step of the definitive staging surgery, which
comprises pelvic and paraaortic lymph node dissection is
deterministic in the new staging system that has been recently
designed by the International Federation of Gynecology andTable 1
Clinicopathological features of uterine adenosarcoma with sex cord-like elements
Case no. Age (cm) Size SCEs (%)
MR
1 52 4 cm endocervical polyp 0.5 cm
nodule area
5 M
2 22 2 cm endomet. mass 50% 7M
3 85 NE 20% 8M
4 75 6 cm endomet. mass 25% 5M
5 70 6 cm endomet. mass 25% 2M
6 41 3 cm endomet. mass 40% 15
7 38 Bulky, endocerv. and endomet. mass 50% 1M
8 40 1.5 cm endomet. mass 10% 3M
9 70 3 cm endomet. mass 5% 2M
10 71 2.5 cm endomet. mass 75% 1M
11 64 8 cm endomet mass 75% 1M
12a 47 4 cm endomet. mass 20% 1M
DWD¼ died with disease; LFU¼ lost to follow-up; LSO¼ left salpingo-oophere
disease; RH¼ radical hysterectomy; RT¼ radiotherapy; SCEs¼ sex cord element
a present case.Obstetrics (2009). However, estrogen and/or progesteron
receptors are frequently expressed in most low-grade stromal
sarcomas [9], this may suggest a probable susceptibility of the
mullarian adenosarcoma to estrogen, thus questioning the safety
of ovarian preservation.
Optimal therapy and the role of adjuvant treatment are not
clear and have not been fully evaluated in adenosarcomas. To
perform TAH with BSO and pelvic lymph node sampling for
stage I disease should be appropriate. Women with superficial
myometrial invasion probably do not require adjuvant
therapy. But those with deep invasion and a high degree of
sarcomatous stromal overgrowth have a greater chance of
recurrence and may benefit from pelvic radiation or chemo-
therapy [8]. Baker et al. [10] concluded on the basis of a series
of six adenosarcoma cases that prevention of recurrence
cannot be achieved by intra- or extracavity radiotherapy. In
a recent study by Han et al. [11], there were nine patients with
adenosarcoma, seven of these were stage I and two were stage
III. Seven patients were treated by a single agent or combi-
nation chemotherapy (cisplatin, pharmorubicin, ifosfamid)
with or without hormone therapy after surgery. The remaining
two patients were treated only by surgery. Radiotherapy in
addition to chemotherapy was applied to only one of two
stage III patients. Five of these seven patients who received
chemotherapy were alive and well with no evidence of
recurrence, while one stage I patient and one stage III patient
developed a recurrent tumor and later died 1.2 years after
surgery.
Interestingly, patients in this review had mostly noninvasive
or superficial invasion and no deep invasion or sarcomatous
overgrowth; hence, none of them received adjuvant chemo- or
radiotherapy. Only one patient (Case 3), treated by curettage
and radiation, had persistent intracavitary tumor at 7 months
and died of an unrelated illness at 16 months. Another patient
(Case 5) was initially treated by polypectomy. After 2 years
the patient presented with similar symptoms and consequently
was diagnosed with sarcoma botryoides and treated byreported in literature.
Adenosarcoma Treatment Follow-up (years)
MI
F/10 HPF  RHþBSOþ partial
vaginectomyþ pelvic
lymphadenectomy
NED ( 1.1 y)
F/10 HPF þ TAHþBSO LFU
F/10 HPF NE D&CþRT DWD (1.3 y)
F/10 HPF þ TAHþBSO NED (3 y)
F/10 HPF  D&C/melphalanþRT/TAHþBSO NED (5 y)
MF/10 HPF  TAHþBSO NED (8.5 y)
F/10 HPF þ TAHþBSO NED (8.5 y)
F/10 HPF  TAHþ LSO NED (9 y)
F/10 HPF þ TAH NED (11 y)
F/10 HPF  TAHþBSO NED (5 y)
F/10 HPF  TAHþBSO NED (3 y)
F/10 HPF þ TAHþBSO NED (3 y)
ctomy; MR¼mitotic rate; MI¼myometrial invasion; NED¼ no evidence of
s.
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she again presented similar complaints and a TAH with BSO
was performed.
Clement and colleagues evaluated 100 patients with uterine
adenosarcoma [1]. Although adenosarcomas have less
tendency to invade, four cases in this series were found to have
metastases, and local recurrency was observed in 23 cases. In
their report approximately one third recurred five or more
years after hysterectomy. Analysis of literature from patients
with MASCEs revealed extremely low recurrency rates
compared with the typical adenosarcomas (23%). If one
patient with recurrent tumor in different histological diagnosis
(Case 5); who had been treated firstly with dilatation and
curettage, later with melphalan and radiotherapy is excluded
from analysis, the recurrence rate is 9% in MASCEs. Myo-
metrial invasion and mitotic rates also were assessed in this
review. Invasion was present in five cases; three superficially
and two into the inner half of the myometrium. As well,
sarcomatous stroma generally exhibited mild degrees of nuclear
pleomorfism and had lower mitotic rates (mean 4) in MASCEs,
than those of typical adenosarcomas (mean 9).
In conclusion, although there is not enough data in the
present literature, benign epithelial differentiations, such as
SCEs may reflect the behavior of the tumor. As in our case,
a more innocent histopathologic architecture can be observed
and may likely be responsible for low recurrences and the
benign clinical course in most of cases, even if they have not
received any postoperative adjuvant therapy.References
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